Novel Siwa propolis and colistin-integrated chitosan nanoparticles: elaboration; in vitro and in vivo appraisal

Aim: The present study aimed to formulate novel cremophore-decorated chitosan nanoparticles of colistin, integrated with Siwa propolis extract, to solve bacterial resistance to colistin. Materials & methods: The novel nanoformula was prepared using an incorporation method. Physicochemical assessment and in vivo studies of the selected nanoformulations were performed. Results: The nanoformulation exhibited a nanosize of 48.3 nm, high ζ potential (43.6 mV), high entrapment efficiency (75%) and complete bacterial growth eradication within 2 h (minimum inhibitory concentration = 6.25 μg/ml). Histological examination showed that incorporation of colistin into the nanoformulation could successfully prevent its nephrotoxicity. Conclusion: Tailoring of proper nanocarrier could successfully revert bacteria from being colistin-resistant to colistin-sensitive. The developed nanoformulation can be considered as a potential antibacterial agent in pneumonia treatment.

Download Full-text

In vitro and in vivo Evaluation of Pramipexole HCl Mucoadhesive Microspheres

International Journal of Pharmaceutical Sciences and Drug Research ◽

10.25004/ijpsdr.2018.100509 ◽

2018 ◽

Vol 10 (05) ◽

Author(s):

K. Subbarao ◽

G. Suresh

Keyword(s):

Drug Delivery ◽

Entrapment Efficiency ◽

In Vivo Studies ◽

The Novel ◽

In Vivo Evaluation ◽

In Vitro Drug Release ◽

Efficient Management ◽

Gastro Retentive

The study was aimed to design and develop the novel gastro retentive mucoadhesive Pramipexole microspheres using ionotropic gelation technique. Based on the results of Micromeretic properties confirmed that microspheres were free flowing with good pack ability. The optimized M13 formulation displayed the % entrapment efficiency 96.07%, % yield 98.01%, swelling index 96.08% and Mucoadhesiveness was 95.42%. The in vitro drug release showed the sustained release of Pramipexole up to 99.16 ± 5.12% within 12 h. FTIR studies revealed incompatibility was not found between drug and excipients. SEM confirmed the particles were of spherical in shape. Optimized formulation (M13) were stable at 40°C ± 2°C/75% RH ± 5% RH for 6 months. In vivo studies were performed and kinetic parameters like Cmax, Tmax, AUC0-t, AUC0-∞ and t1/2 were calculated. The marketed product Cmax (2.19 ± 0.01 ng/ml) was higher than optimized formulation (2.0 ± 0.01 ng/ml). The optimized formulation AUC0-t (20.15 ± 1.12 ng.hr/ml), AUC0-∞ (27.42 ± 1.16 ng.hr/ml) was significantly higher than that of marketed product AUC0-t (13.21 ± 1.26 ng.hr/ml) and AUC0-∞ (19.15 ± 1.13 ng.hr/ml) respectively. Which indicated the optimized formulation bioavailability was higher than marketed product. Microspheres would be a promising drug delivery system which plays potentially significant role in pharmaceutical drug delivery in the efficient management of Parkinson’s disease.

Download Full-text

Formulation and In Vivo Evaluation of Mucoadhesive Micro-spheres of Rebamipide, a Mucoprotective Drug for GIT Disorders

International Journal of Pharmaceutical Sciences and Nanotechnology ◽

10.37285/ijpsn.2018.11.3.2 ◽

2018 ◽

Vol 11 (3) ◽

pp. 4089-4097

Author(s):

Bhikshapathi D. V. R. N. ◽

Kanteepan P

Keyword(s):

Drug Release ◽

Entrapment Efficiency ◽

In Vivo Studies ◽

Amino Acid Derivative ◽

Release Mechanism ◽

In Vivo Evaluation ◽

In Vitro Drug Release ◽

Percentage Yield

Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. The current research study aimed to develop novel gastro-retentive mucoadhesive microspheres of rebamipide using ionotropic gelation technique. Studies of micromeritic properties confirmed that microspheres were free flowing with good packability. The in vitro drug release showed the sustained release of rebamipide up to 99.23 ± 0.13% within 12 h whereas marketed product displayed the drug release of 95.15 ± 0.23% within 1 h. The release mechanism from microspheres followed the zero-order and Korsmeyer-Peppas (R2 = 0.915, 0.969), respectively. The optimized M12 formulation displayed optimum features, such as entrapment efficiency 97%, particle size 61.94 ± 0.11 µm, percentage yield 98%, swelling index 95% and mucoadhesiveness was 97%. FTIR studies revealed no major incompatibility between drug and excipients. SEM confirmed the particles were of spherical in shape. Optimized formulation (M12) were stable at 40°C ± 2°C/75% RH ± 5% RH for 6 months. In vivo studies were performed and kinetic parameters like Cmax, Tmax, AUC0-t, AUC0-∞, t1/2, and Kel were calculated. The marketed product Cmax (3.15 ± 0.05 ng/mL) was higher than optimized formulation (2.58 ± 0.03 ng/mL). The optimized formulation AUC0-t (15.25 ± 1.14 ng.hr/mL), AUC0-∞ (19.42 ± 1.24 ng.hr/mL) was significantly higher than that of marketed product AUC0-t (10.21 ± 1.26 ng.hr/mL) and AUC0-∞ (13.15 ± 0.05 ng.hr/mL). These results indicate an optimized formulation bioavailability of 2.5-fold greater than marketed product.

Download Full-text

Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation

Antibiotics ◽

10.3390/antibiotics10040439 ◽

2021 ◽

Vol 10 (4) ◽

pp. 439

Author(s):

Christopher G. Bunick ◽

Jonette Keri ◽

S. Ken Tanaka ◽

Nika Furey ◽

Giovanni Damiani ◽

...

Keyword(s):

Broad Spectrum ◽

Bacterial Resistance ◽

Antibiotic Use ◽

In Vivo Studies ◽

Infection Model ◽

Severe Acne ◽

Rat Paw Edema ◽

Infection And Inflammation

Prolonged broad-spectrum antibiotic use is more likely to induce bacterial resistance and dysbiosis of skin and gut microflora. First and second-generation tetracycline-class antibiotics have similar broad-spectrum antibacterial activity. Targeted tetracycline-class antibiotics are needed to limit antimicrobial resistance and improve patient outcomes. Sarecycline is a narrow-spectrum, third-generation tetracycline-class antibiotic Food and Drug Administration (FDA)-approved for treating moderate-to-severe acne. In vitro studies demonstrated activity against clinically relevant Gram-positive bacteria but reduced activity against Gram-negative bacteria. Recent studies have provided insight into how the structure of sarecycline, with a unique C7 moiety, interacts with bacterial ribosomes to block translation and prevent antibiotic resistance. Sarecycline reduces Staphylococcus aureus DNA and protein synthesis with limited effects on RNA, lipid, and bacterial wall synthesis. In agreement with in vitro data, sarecycline demonstrated narrower-spectrum in vivo activity in murine models of infection, exhibiting activity against S. aureus, but reduced efficacy against Escherichia coli compared to doxycycline and minocycline. In a murine neutropenic thigh wound infection model, sarecycline was as effective as doxycycline against S. aureus. The anti-inflammatory activity of sarecycline was comparable to doxycycline and minocycline in a rat paw edema model. Here, we review the antibacterial mechanisms of sarecycline and report results of in vivo studies of infection and inflammation.

Download Full-text

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor

Journal of Thrombosis and Haemostasis ◽

10.1111/j.1538-7836.2005.01166.x ◽

2005 ◽

Vol 3 (3) ◽

pp. 514-521 ◽

Cited By ~ 399

Author(s):

E. PERZBORN ◽

J. STRASSBURGER ◽

A. WILMEN ◽

J. POHLMANN ◽

S. ROEHRIG ◽

...

Keyword(s):

Factor Xa ◽

In Vivo Studies ◽

Factor Xa Inhibitor ◽

The Novel ◽

Direct Factor ◽

Antithrombotic Agent

Download Full-text

Systemic α1A-adrenoceptor antagonist inhibits neointimal growth after balloon injury of rat carotid artery

AJP Heart and Circulatory Physiology ◽

10.1152/ajpheart.00658.2002 ◽

2003 ◽

Vol 284 (1) ◽

pp. H385-H392 ◽

Cited By ~ 18

Author(s):

John C. Teeters ◽

Cauveh Erami ◽

Hua Zhang ◽

James E. Faber

Keyword(s):

Vascular Disease ◽

In Vivo Studies ◽

The Novel ◽

Balloon Injury ◽

Systemic Hemodynamic ◽

Adrenoceptor Antagonist ◽

And Migration ◽

Wall Injury

Previous in vitro and in vivo studies have shown that norepinephrine, acting through α1A-adrenoceptors, stimulates hypertrophy, proliferation, and migration of vascular smooth muscle cells and adventitial fibroblasts and may contribute to neointimal growth, lumen loss, and inward remodeling caused by iatrogenic wall injury and vascular disease. Our present aim was to determine whether intravenous administration of the α1A-adrenoceptor antagonist KMD-3213, at dosages without systemic hemodynamic effects, inhibits wall growth after injury. Inhibition of α1A-adrenoceptors with 12.8 and 32 μg/kg KMD-3213 had no effect on arterial pressure or renal and hindquarter resistances in anesthetized rats. A second group then received carotid balloon injury and continuous intravenous KMD-3213 at 4 and 10 μg · kg−1 · h−1for 2 wk. Mean, systolic, and diastolic arterial pressures and heart rate of conscious unrestrained rats were unaffected. KMD-3213 reduced neointima growth by ∼30 and 46% at the two doses ( P< 0.01). These data support the novel hypothesis that a direct α1A-adrenoceptor-dependent trophic action of catecholamines is augmented by injury and may contribute significantly to hypertrophic vascular disease.

Download Full-text

Chloramphenicol Resurrected: A Journey from Antibiotic Resistance in Eye Infections to Biofilm and Ocular Microbiota

Microorganisms ◽

10.3390/microorganisms7090278 ◽

2019 ◽

Vol 7 (9) ◽

pp. 278 ◽

Cited By ~ 3

Author(s):

Lorenzo

Keyword(s):

Pathogenic Bacteria ◽

Bacterial Resistance ◽

Antimicrobial Agents ◽

In Vivo Studies ◽

Antibiofilm Activity ◽

Eye Infections ◽

Treatment And Prevention ◽

Old Drugs

The advent of multidrug resistance among pathogenic bacteria is devastating the worth of antibiotics and changing the way of their administration, as well as the approach to use new or old drugs. The crisis of antimicrobial resistance is also due to the unavailability of newer drugs, attributable to exigent regulatory requirements and reduced financial inducements. The emerging resistance to antibiotics worldwide has led to renewed interest in old drugs that have fallen into disuse because of toxic side effects. Thus, comprehensive efforts are needed to minimize the pace of resistance by studying emergent microorganisms and optimize the use of old antimicrobial agents able to maintain their profile of susceptibility. Chloramphenicol is experiencing its renaissance because it is widely used in the treatment and prevention of superficial eye infections due to its broad spectrum of activity and other useful antimicrobial peculiarities, such as the antibiofilm properties. Concerns have been raised in the past for the risk of aplastic anemia when chloramphenicol is given intravenously. Chloramphenicol seems suitable to be used as topical eye formulation for the limited rate of resistance compared to fluoroquinolones, for its scarce induction of bacterial resistance and antibiofilm activity, and for the hypothetical low impact on ocular microbiota disturbance. Further in-vitro and in vivo studies on pharmacodynamics properties of ocular formulation of chloramphenicol, as well as its real impact against biofilm and the ocular microbiota, need to be better addressed in the near future.

Download Full-text

Formulation of sustained-release microspheres of cefixime with enhanced oral bioavailability and antibacterial potential

Therapeutic Delivery ◽

10.4155/tde-2019-0057 ◽

2019 ◽

Vol 10 (12) ◽

pp. 769-782

Author(s):

Karan Razdan ◽

Nikhil S Sahajpal ◽

Kuldeep Singh ◽

Harmanpreet Singh ◽

Harjeet Singh ◽

...

Keyword(s):

Sustained Release ◽

Entrapment Efficiency ◽

Salmonella Typhi ◽

In Vivo Studies ◽

In Vitro Drug Release ◽

Dosing Frequency ◽

Twofold Decrease ◽

Antibacterial Potential

Aim: The present work focused on the development of sustained-release microsphere formulation of cefixime to provide reduction in dosing frequency, improved antibacterial activity and patient compliance. Methodology & results: Microspheres were prepared by modified emulsion solvent evaporation method and evaluated by in vitro and in vivo studies. Optimized formulation (FK-07) was found to have entrapment efficiency of 81.12 ± 0.93% and particle size of 166.82 ± 0.86 μm. FK-07 sustained release up to 24 h as demonstrated by in vitro drug release and in vivo pharmacokinetic study in rats. FK-07 showed approximately twofold increase in bioavailability and twofold decrease in MIC90 value against Escherichia coli, Klebsiella pneumoniae and Salmonella typhi in comparison to marketed formulation. Conclusion: Sustaining the release of cefixime using microspheres enhanced its bioavailability, antibacterial efficacy and will help in reducing its dosing frequency.

Download Full-text

Development and Characterization of a Clobetasol Propionate Nanostructured Lipid Carrier-based Gel for the Treatment of Plaque Psoriasis

Current Molecular Pharmacology ◽

10.2174/1874467213666200628135552 ◽

2020 ◽

Vol 13 ◽

Author(s):

Ankita Dadwal ◽

Neeraj Mishra ◽

Raj Kumar Narang

Keyword(s):

Skin Permeation ◽

In Vitro Release ◽

Entrapment Efficiency ◽

Homogenization Method ◽

Clobetasol Propionate ◽

In Vivo Studies ◽

Nanostructured Lipid Carrier ◽

Safe Delivery

Background: Psoriasis is an autoimmune disease of the skin with lapsing episodes of hyperkeratosis, irritation, and inflammation. Numerous traditional and novel drug delivery systems have been used for better penetration through psoriatic barrier cells and also for retention in the skin. As there is no effective remedy for better penetration and retention is there because of the absence of an ideal carrier for effective and safe delivery of antipsoriatic drugs. Objectives: The main objective of this project is to develop Squalene integrated NLC based carbopol 940 gel to create a local drug depot in skin for improved efficacy against psoriasis. Methods: Homogenization method is used for the formulation of Nanostructured Lipid Carrier and were characterized on the basis of size, entrapment efficiency, polydispersity index (PDI), viscosity, spreadability, DSC, zeta potential, % in vitro release, in vitro skin permeation and retention studies, physical storage stability studies and in vivo studies can use other alternative models for induction of psoriasis by severe redness, swelling macroscopically and microvascular dilation edema lasting for 10 days. Further histopathology study was done to basses of changes in the skin. Conclusion: The optimized formulation of nanostructured lipid carrier-based gel has shown significant sustained release of clobetasol propionate. Further, this formulation has also shown retention in skin because of squalene as it is sebum derived lipid show affinity towards the sebaceous gland.

Download Full-text

In vitro hydrodynamics of the Embol-X cannula

Perfusion ◽

10.1191/0267659102pf537xx ◽

2002 ◽

Vol 17 (2) ◽

pp. 153-156 ◽

Cited By ~ 2

Author(s):

Anja Gerdes ◽

Thorsten Hanke ◽

Hans-H Sievers

Keyword(s):

In Vivo Studies ◽

Clinical Effects ◽

Pressure Gradients ◽

The Novel ◽

Flow Rates ◽

Mock Circulation ◽

Aortic Cannula ◽

Novel Concept

Background: Prevention of intraoperative plaque dislodgement in patients with atherosclerotic ascending aorta by development of innovative aortic cannula designs gains growing interest in cardiac surgery. To increase knowledge about the hydrodynamics of the innovative Embol-X™ cannula, which includes an intra-aortic filter device targeting at atheromatous emboli capture, was the aim of the present study. Methods: Pressure gradients and back pressures of the Embol-X™ cannula were measured at varying flow rates in a mock circulation and compared with two commonly used single-stream cannulae. Results: At a flow rate of 5.5 l/min, pressure gradients across the Argyle™ and the RMI cannulae were 48% and 62% and back pressures 25% and 47% lower than the corresponding values across the Embol-X™ cannula. Conclusions: The novel concept of integrating a filter device may provide clinical advantages concerning neurologic outcome. Further in vivo studies seem to be desirable to obtain more information concerning the clinical effects of the Embol-X™ cannula hydrodynamics.

Download Full-text